Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

OBJECTIVE: We describe a phase II clinical trial of the combination of ribociclib and letrozole for treatment of relapsed oestrogen receptor (ER)-positive ovarian cancer (OC) and endometrial cancer (EC). The primary endpoint was the proportion of patients alive, progression-free survival (PFS), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Colon-Otero, Gerardo, Zanfagnin, Valentina, Hou, Xiaonan, Foster, Nathan R, Asmus, Erik J, Wahner Hendrickson, Andrea, Jatoi, Aminah, Block, Matthew S, Langstraat, Carrie L, Glaser, Gretchen E, Dinh, Tri A, Robertson, Matthew W, Camoriano, John K, Butler, Kristina A, Copland, John A, Weroha, S John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592247/
https://www.ncbi.nlm.nih.gov/pubmed/33109627
http://dx.doi.org/10.1136/esmoopen-2020-000926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592247/
https://www.ncbi.nlm.nih.gov/pubmed/33109627
http://dx.doi.org/10.1136/esmoopen-2020-000926

Ejemplares similares